Arizona’s Intoxicating Hemp Crossfire: AG Opinion vs. SB 1702 and What Retailers Can Still Sell

Arizona’s intoxicating hemp market faces a tumultuous crossroads in 2025. Between the enforcement echo of a sweeping 2024 Attorney General (AG) opinion and the uncertain future of SB 1702, manufacturers, retailers, and consumers are left with pressing compliance and business questions. This post walks through the evolving regulatory landscape, what businesses must do right now, and what may be on the horizon for Arizona intoxicating hemp 2025.

The AG’s 2024 Opinion: The De Facto Policy

In 2024, Arizona’s Attorney General released an influential opinion: any intoxicating products synthesized from hemp—such as delta-8 THC, high-potency gummies, and THC beverages—cannot be legally sold outside the state’s tightly regulated dispensary system. The AG anchored this opinion in the overlap of state cannabis and hemp laws and the imperative for safety and public health.

The impact was immediate and clear:

• Retailers selling non-dispensary intoxicating hemp had to pull products or face enforcement.
• Manufacturers and hemp-derived THC brands were left questioning their legal standing.
• Consumers encountered shrinking shelves and uncertainty about product access.

For the full AG opinion text and analysis, see the Arizona Office of the Attorney General releases and the Arizona Department of Health Services (ADHS) hemp guidance.

SB 1702 (2025): Promise of Regulation, Not Law Yet

In response, Arizona lawmakers introduced SB 1702 in 2025—a bill creating a structured regulatory framework for intoxicating hemp-derived products. The proposed legislation includes:

• Licensing for hemp retailers and manufacturers
• Mandatory third-party Certificates of Analysis (COAs) for potency and contaminants
• State-specific testing protocols (requiring testing in Arizona-accredited labs)
• New fee structures to fund oversight
• Clear labeling and packaging rules for consumer safety
• Penalties for violations and unlicensed sales
• Authority to the Arizona Department of Health Services (ADHS) and Department of Agriculture (ADA) to conduct inspections, oversee compliance, and enforce rules

What’s Not Happened Yet:

As of September 2025, SB 1702 remains under legislative consideration. Final passage and subsequent regulatory rulemaking are pending. This means the AG’s opinion—limiting legal sales of intoxicating hemp-derived products to the licensed dispensary channel—continues to define enforcement risk.

Licensing and Compliance: What Is — and Isn’t — Allowed

Where Can Intoxicating Hemp Be Sold?

Currently, intoxicating hemp-derived THC products (delta-8, THC-O, HHC, high-dose gummies, and similar items):

• Cannot be sold in general retail stores, headshops, vape shops, or online for direct-to-consumer shipment within Arizona
• May only be sold through Arizona’s licensed medical or adult-use dispensaries (subject to all relevant ADHS cannabis regulations)
• Immediate enforcement risk for retailers “outside” the dispensary channel

For example, an independent CBD store or health food shop cannot legally sell delta-8 gummies or THC seltzers. Attempting to do so invites product seizure, fines, and possible criminal referral.

License Types (If SB 1702 Passes)

If SB 1702 is enacted, the following license categories are likely:

• Retailer licenses for non-dispensary hemp shops selling qualifying products
• Manufacturer/processor licenses for those making, packaging, or labeling products
• Testing laboratory accreditation by Arizona agencies
• Product registration/certification requirements before public sale

Application timelines and windows will be announced by ADHS/ADA upon the bill’s passage. Early engagement, including compliance audits and records preparation, will be essential for applicants hoping to make a seamless transition to the new license structure.

Certificates of Analysis (COAs): The Arizona Standard

Arizona-specific COAs are non-negotiable for all intoxicating hemp-derived THC products under both the AG opinion and the prospective SB 1702 framework.

COA Requirements:

• Third-party lab testing by a licensed, Arizona-accredited laboratory
• Full cannabinoid profile (total THC, delta-8, delta-9, and other analogs)
• Comprehensive contaminant screening (pesticides, solvents, heavy metals, microbes)
• Batch number and lot traceability
• Must match product labeling and packaging exactly

Products without a valid, batch-specific Arizona COA (or using out-of-state or generic COAs) are at high risk of enforcement action.

Learn more about ADHS cannabis lab accreditation

Retailer Action Items: What to Do Now

1. Audit All Inventory

• Remove “intoxicating” SKUs that fall outside legal dispensary access.
• Segregate non-intoxicating, full-spectrum, and standard CBD items (verify via COA and cannabinoid profile).

2. Confirm Arizona Compliance

• Require all suppliers to provide Arizona-specific COAs for each batch and product.
• Maintain updated documentation for inspections and respond promptly to ADHS or ADA information requests.

3. Monitor SB 1702 Progress and Rulemaking

• Subscribe to legislative updates from the Arizona State Legislature, ADHS, and Arizona Department of Agriculture.
• Prepare for the possible need to apply for new licenses, pay regulatory fees, and update testing and labeling procedures.

4. Train Your Staff

• Ensure all team members are aware of the current enforcement landscape and are able to communicate accurately with customers.

5. Prepare for Local Enforcement

• Watch for county-level enforcement actions—Maricopa and Pima counties, for example, have increased spot checks and seizures.
• Develop an enforcement response plan, including immediate product removal and legal consultation if needed (but remember, this post is not legal advice).

Manufacturer & Supply Chain: Strategic Planning for 2025

Manufacturers and distributors need proactive compliance and contingency strategies:

• Work only with Arizona-accredited testing laboratories for all intoxicating SKUs.
• Update packaging to anticipate new content, warning, and QR code requirements likely under SB 1702.
• Document and verify your supply chain for all components (inputs, flavors, carriers), as adulterants and synthetic processes will be under scrutiny.
• Budget for new fees—retail registration, manufacturer licensing, and product certification may add line-item costs if SB 1702 is enacted.

Consumer Impact: Availability, Legality, and Safety

For Arizona consumers:

• Intoxicating hemp products (not purchased from a state-licensed dispensary) currently risk being seized and their sale prosecuted.
• Standard, non-intoxicating CBD products (with verified low THC <0.3%) remain widely available, but always request to see the COA before purchase.
• Expect further changes—if SB 1702 passes, a wave of new packaging, warning, and age-gating protocols will roll out.

Enforcement & Penalties: The Current Risk Landscape

State and local authorities are actively monitoring the market. Recurrent enforcement trends include:

• Unannounced retailer inspections
• Product embargoes and removal from shelves
• Civil penalties and potential criminal referral for blatant violations

Though enforcement is not always uniform, retailers and manufacturers can’t count on a “grace period” as lawmakers debate SB 1702. Several counties—including Maricopa and Pinal—have already conducted compliance sweeps with confiscation of illegal intoxicating products.

Key point: Do not assume that “legal in other states” equals compliant in Arizona. The AG opinion is binding until/unless SB 1702 passes and new rules are adopted.

Looking Ahead: Prepare Now, Don’t Wait

• Stay vigilant: The period before SB 1702 passes (if it does) remains risky for retailers of intoxicating hemp.
• Engage with regulators: Participate in any forthcoming stakeholder meetings announced by ADHS and ADA.
• Document everything: Keep inventory logs, batch COAs, supplier records, and compliance checklists easily accessible.
• Be agile: Regulatory requirements will evolve rapidly—adapt operations and product mixes as the law shifts.

For live compliance tracking and regulatory updates, bookmark https://cannabisregulations.ai/arizona

Takeaways: Must-Know Points for Arizona Cannabis Businesses

• The 2024 AG opinion prohibits the sale of intoxicating hemp outside the state cannabis dispensary system.
• SB 1702, if passed, will create a new licensing and testing framework—but right now, selling intoxicating hemp in general retail remains illegal.
• Arizona-specific COAs are mandatory, not optional, for all qualifying products.
• Enforcement at the local and county level is active. Businesses caught out of compliance face product seizure and further penalties.
• Preparation—through inventory audits, documentation, supplier vetting, and staff training—mitigates enforcement risk and positions your business for the future.

Stay ahead, stay compliant. For real-time Arizona regulatory guidance and personalized compliance tools, visit CannabisRegulations.ai today.